Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 786 across all filing types
Latest filing 2016-01-07 Board/Management Inform…
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 5, 2016, by Lipocine Inc. The content focuses on the approval of a cash bonus plan for executive officers, detailing target bonuses and performance criteria. This type of filing is typically used to announce significant corporate events such as changes in management compensation plans. It is not a full annual or quarterly report, audit report, earnings release, or other detailed financial report. The key item is Item 5.02, which relates to departure or appointment of directors or officers and compensatory arrangements. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes or arrangements related to senior management.
2016-01-07 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce specific events. The text indicates it is a short filing (2332 characters) announcing a press release about a clinical study milestone (first subject dosed in Phase 2b). It includes no financial statements or detailed financial data, only a reference to a press release as an exhibit. The document is not a full financial report, earnings release, or management discussion. It is a regulatory announcement of a corporate event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2016-01-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 30, 2015, by Lipocine Inc. It reports a material modification to rights of security holders, specifically the adoption of a stockholder rights plan (a poison pill) and the creation of a new Series A Junior Participating Preferred Stock. The document includes detailed descriptions of the rights plan, the terms of the preferred stock, and references to exhibits such as the Certificate of Designation. The Form 8-K is a current report used to announce significant corporate events and changes, including amendments to articles of incorporation or bylaws, which is consistent with the content here. This is not a full annual or quarterly report, nor an earnings release, nor a proxy statement. It is a regulatory filing announcing a material event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7655 characters) and content confirm it is not a brief announcement but a detailed regulatory filing. Confidence is high due to the clear identification of the form type and content.
2015-12-01 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 30, 2015. It announces that the company will be presenting at the 27th Annual Piper Jaffray Healthcare Conference and includes the presentation materials as an exhibit. The document is short (2304 characters) and primarily serves as an announcement of the presentation and the attached materials, not the presentation itself. According to the 'Menu vs Meal' rule, such announcements are classified as Regulatory Filings (RNS) rather than Investor Presentations (IP). Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-11-30 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 13, 2015, reporting the adoption of a stockholder rights plan by the Board of Directors of Lipocine, Inc. The content focuses on the entry into a material definitive agreement (the Rights Plan) designed to deter hostile takeovers. It includes detailed terms of the Rights Plan and references exhibits such as the Stockholder Rights Agreement and a press release. There are no financial statements or earnings data presented, nor is this a full annual or quarterly report. The primary subject is a corporate governance action related to a shareholder rights plan, which is a material definitive agreement. According to the filing definitions, announcements of material agreements and similar corporate actions are best classified under Capital/Financing Update (CAP) because it relates to changes in capital structure and shareholder rights. The document is not a report publication announcement or a regulatory filing fallback, as it contains substantive information about the Rights Plan. Therefore, the appropriate classification is CAP with high confidence.
2015-11-13 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 12, 2015, reporting the financial and operational results for the third quarter ended September 30, 2015. It references a press release (Exhibit 99.1) announcing these results. The text itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information via a press release. The document length is 2353 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as an Earnings Release (ER) since it is the initial announcement of quarterly financial results, even though the detailed data is in the press release exhibit. The 8-K form is commonly used for earnings releases. Therefore, the classification is ER with high confidence.
2015-11-12 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.